

Fernando Antónanzas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/537345/publications.pdf>

Version: 2024-02-01

92
papers

1,785
citations

361413

20
h-index

330143

37
g-index

121
all docs

121
docs citations

121
times ranked

1900
citing authors

#	ARTICLE	IF	CITATIONS
1	Seeking efficiency gains outside drugs and diagnostics. European Journal of Health Economics, 2022, , 1.	2.8	0
2	Diagnostic Testing for Sepsis: A Systematic Review of Economic Evaluations. Antibiotics, 2022, 11, 27.	3.7	1
3	Efficiency of Diagnostic Testing for Helicobacter pylori Infectionsâ€”A Systematic Review. Antibiotics, 2021, 10, 55.	3.7	6
4	Hispa-NICE: A Pipe Dream or a Realistic and Necessary Initiative?. Pharmacoeconomics, 2021, 39, 481-483.	3.3	0
5	Economic Analyses of Respiratory Tract Infection Diagnostics: A Systematic Review. Pharmacoeconomics, 2021, 39, 1411-1427.	3.3	8
6	Using point-of-care diagnostic testing for improved antibiotic prescription: an economic model. Health Economics Review, 2021, 11, 29.	2.0	12
7	Health-Economic Analyses of Diagnostics: Guidance on Design and Reporting. Pharmacoeconomics, 2021, 39, 1355-1363.	3.3	5
8	Analysis of the Prescription of Antibiotics During the Implementation of COVID-19 Personal Protection Measures in a Regional Health System. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 927-936.	1.9	4
9	Effects of economic and health policies on the consumption of antibiotics in a Spanish region. Expert Review of Pharmacoeconomics and Outcomes Research, 2020, 20, 379-386.	1.4	5
10	Policies to Reduce Antibiotic Consumption: The Impact in the Basque Country. Antibiotics, 2020, 9, 423.	3.7	2
11	Health economic evaluation of gene replacement therapies: methodological issues and recommendations. Journal of Market Access & Health Policy, 2020, 8, 1822666.	1.5	18
12	Overcoming fragmentation of health research in Europe: lessons from COVID-19. Lancet, The, 2020, 395, 1970-1971.	13.7	14
13	Efficiency ratio and rocketing drug prices: old concerns and new possibilities. European Journal of Health Economics, 2020, 21, 1273-1277.	2.8	4
14	Availability of biological cancer drugs under research: registration and price in Brazil, Colombia, and Mexico. Physis, 2020, 30, .	0.3	0
15	Stakeholder opinions on value in healthcare. European Journal of Hospital Pharmacy, 2019, 26, ejhpharm-2017-001295.	1.1	2
16	Implementation of risk-sharing contracts as perceived by Spanish hospital pharmacists. Health Economics Review, 2019, 9, 25.	2.0	9
17	The Use of Risk-Sharing Contracts in Healthcare: Theoretical and Empirical Assessments. Pharmacoeconomics, 2019, 37, 1469-1483.	3.3	36
18	Pre-approval incentives to promote adoption of personalized medicine: a theoretical approach. Health Economics Review, 2019, 9, 28.	2.0	3

#	ARTICLE	IF	CITATIONS
19	Personalized Medicine and Pay for Performance: Should Pharmaceutical Firms be Fully Penalized when Treatment Fails?. <i>Pharmacoeconomics</i> , 2018, 36, 733-743.	3.3	18
20	EMA Priority Medicines scheme (PRIME): will more paying-for-performance agreements be needed due to immature data?. <i>European Journal of Health Economics</i> , 2018, 19, 905-907.	2.8	4
21	Economic evaluation of personalized medicine: a call for real-world data. <i>European Journal of Health Economics</i> , 2017, 18, 1065-1067.	2.8	13
22	Defining and Measuring the Affordability of New Medicines: A Systematic Review. <i>Pharmacoeconomics</i> , 2017, 35, 777-791.	3.3	6
23	On vaccination programs in the EU Member States: the case of the human papilloma virus. <i>European Journal of Health Economics</i> , 2017, 18, 801-803.	2.8	0
24	The Value of Medicines: A Crucial but Vague Concept. <i>Pharmacoeconomics</i> , 2016, 34, 1227-1239.	3.3	21
25	Implementing personalized medicine with asymmetric information on prevalence rates. <i>Health Economics Review</i> , 2016, 6, 35.	2.0	2
26	Improving health care systems by building "more Europe". <i>European Journal of Health Economics</i> , 2016, 17, 787-789.	2.8	3
27	Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain. <i>Clinical Drug Investigation</i> , 2016, 36, 41-53.	2.2	23
28	Efficient health research and improving Europeans' health. <i>European Journal of Health Economics</i> , 2015, 16, 913-915.	2.8	0
29	Is personalized medicine a panacea for health management? Some thoughts on its desirability. <i>European Journal of Health Economics</i> , 2015, 16, 455-457.	2.8	4
30	Some economics on personalized and predictive medicine. <i>European Journal of Health Economics</i> , 2015, 16, 985-994.	2.8	18
31	Cost-Effectiveness Analysis of Levobupivacaine 0.5%, a Local Anesthetic, Infusion in the Surgical Wound After Modified Radical Mastectomy. <i>Clinical Drug Investigation</i> , 2015, 35, 575-582.	2.2	1
32	Economic Features of Antibiotic Resistance: The Case of Methicillin-Resistant <i>Staphylococcus aureus</i> . <i>Pharmacoeconomics</i> , 2015, 33, 285-325.	3.3	50
33	Should the patent system for pharmaceuticals be replaced? A theoretical approach. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2014, 14, 617-626.	1.4	4
34	Postoperative Analgesia by Infusion of Local Anesthetic into the Surgical Wound after Modified Radical Mastectomy. <i>Plastic and Reconstructive Surgery</i> , 2014, 134, 862e-870e.	1.4	16
35	Methodological reviews of economic evaluations in health care: what do they target?. <i>European Journal of Health Economics</i> , 2014, 15, 829-840.	2.8	12
36	Core Discrete Event Simulation Model for the Evaluation of Health Care Technologies in Major Depressive Disorder. <i>Value in Health</i> , 2014, 17, 183-195.	0.3	10

#	ARTICLE	IF	CITATIONS
37	Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic model. BMC Infectious Diseases, 2013, 13, 175.	2.9	19
38	Channeling health economics research initiatives to improve decision-making processes in the EU. European Journal of Health Economics, 2013, 14, 847-852.	2.8	5
39	Pharmaceutical Costs of Assisted Reproduction in Spain. Clinical Drug Investigation, 2013, 33, 789-794.	2.2	3
40	The impact of the economic downturn on healthcare in Spain: consequences and alternatives. Expert Review of Pharmacoeconomics and Outcomes Research, 2013, 13, 433-439.	1.4	9
41	Genetic testing in the European Union: does economic evaluation matter?. European Journal of Health Economics, 2012, 13, 651-661.	2.8	13
42	Coping with uncertainty on health decisions: assessing new solutions. European Journal of Health Economics, 2012, 13, 375-378.	2.8	2
43	Cost-Effectiveness of Tapentadol in Severe Chronic Pain in Spain: A Cost Analysis of Data From RCTs. Clinical Therapeutics, 2012, 34, 926-943.	2.5	21
44	PCN84 Population Vaccination Program for Human Papillomavirus in Spanish Girls: An Efficiency Study. Value in Health, 2011, 14, A449.	0.3	0
45	PIN112 Use of Dynamic Models to Measure Health Outcomes of Pneumococcal Vaccination in Spanish Adult Population. Value in Health, 2011, 14, A286.	0.3	1
46	PHP150 Pharmaceutical Pricing Under Uncertainty: Risk-Sharing Contracts. Value in Health, 2011, 14, A360.	0.3	0
47	PHP153 Some Shortages and Alternatives to the Patent System for Pharmaceuticals. Value in Health, 2011, 14, A361.	0.3	0
48	PRM58 Methodological Reviews of Economic Evaluations in Health Care: Are They Useful?. Value in Health, 2011, 14, A431.	0.3	0
49	Pharmaceutical patents, R&D incentives and access to new drugs: new ways of progress at the crossroad. European Journal of Health Economics, 2011, 12, 393-395.	2.8	3
50	Innovation, loyalty and generic competition in pharmaceutical markets. SERIES, 2011, 2, 75-95.	1.4	3
51	Healthy vs. unhealthy food: a strategic choice for firms and consumers. Health Economics Review, 2011, 1, 4.	2.0	4
52	Should health authorities offer risk-sharing contracts to pharmaceutical firms? A theoretical approach. Health Economics, Policy and Law, 2011, 6, 391-403.	1.8	39
53	Spanish recommendations on economic evaluation of health technologies. European Journal of Health Economics, 2010, 11, 513-520.	2.8	194
54	Feeding the economics of obesity in the EU in a healthy way. European Journal of Health Economics, 2010, 11, 351-353.	2.8	10

#	ARTICLE	IF	CITATIONS
55	New Prescription for the Spanish Drug Sector. Pharmacoeconomics, 2010, 28, 977-980.	3.3	3
56	Transferability indices for health economic evaluations: methods and applications. Health Economics (United Kingdom), 2009, 18, 629-643.	1.7	30
57	Cost-Utility Analysis of Eprosartan Compared to Enalapril in Primary Prevention and Nitrendipine in Secondary Prevention in Europeâ€™The HEALTH Model. Value in Health, 2009, 12, 857-871.	0.3	15
58	Economic Evaluations in the EURONHEED. Pharmacoeconomics, 2009, 27, 561-570.	3.3	11
59	Le valutazioni economiche nel database EURONHEED. Pharmacoeconomics Italian Research Articles, 2009, 11, 187-196.	0.2	0
60	Alcohol consumption in the EU: health economics and policy issues under a permanent debate. European Journal of Health Economics, 2008, 9, 1-6.	2.8	6
61	Dynamic Modelling of Infectious Diseases. Pharmacoeconomics, 2008, 26, 45-56.	3.3	34
62	Comentario. Eficiencia de la acarbosa asociada con el tratamiento oral de la diabetes mellitus tipo 2 en EspaÃ±a. Gaceta Sanitaria, 2007, 21, 105.	1.5	0
63	Tobacco policies in the European Union: a need for state and continental harmonisation?. European Journal of Health Economics, 2007, 8, 301-304.	2.8	1
64	Economic aspects of the new Spanish laws on pharmaceutical preparations. European Journal of Health Economics, 2007, 8, 297-300.	2.8	18
65	Healthcare Rationing in Spain. Pharmacoeconomics, 2006, 24, 537-548.	3.3	7
66	Cost-effectiveness of memantine in community-based Alzheimerâ€™s disease patients: an adaptation in Spain. European Journal of Health Economics, 2006, 7, 137-144.	2.8	27
67	Transferability of Economic Evaluation Results. Pharmacoeconomics, 2004, 22, 827-827.	3.3	15
68	Hepatitis B Management Costs in France, Italy, Spain, and the United Kingdom. Journal of Clinical Gastroenterology, 2004, 38, S169-S174.	2.2	19
69	Análisis de costes y resultados en la evaluación económica de las intervenciones sanitarias. Medicina Clínica, 2004, 122, 423-429.	0.6	11
70	Análisis coste-efectividad en la evaluación económica de intervenciones sanitarias. Medicina Clínica, 2004, 122, 505-510.	0.6	16
71	Utilización de las evaluaciones económicas de intervenciones sanitarias. Medicina Clínica, 2004, 122, 789-795.	0.6	6
72	Challenges to Achieving Value in Drug Spending in a Decentralized Country: The Spanish Case. Value in Health, 2003, 6, S52-S63.	0.3	15

#	ARTICLE	IF	CITATIONS
73	PIN23 SPANISH HEALTH INTERVENTIONS FOR CHRONIC HEPATITIS B AND THEIR ASSOCIATED COSTS. Value in Health, 2003, 6, 754.	0.3	0
74	PIN38 COST-EFFECTIVENESS ANALYSIS OF PEGYLATED INTERFERONS COMBINED WITH RIBAVIRIN IN THE TREATMENT OF HEPATITIS C. Value in Health, 2003, 6, 759.	0.3	1
75	PNM10 COST EFFECTIVENESS OF MEMANTINE IN THE TREATMENT OF MODERATELY SEVERE AND SEVERE ALZHEIMER'S DISEASE IN SPAIN. Value in Health, 2003, 6, 765.	0.3	4
76	Impacto de la diabetes mellitus tipo 2 en la calidad de vida de los pacientes tratados en las consultas de atención primaria en España. Atención Primaria, 2003, 31, 493-499.	1.4	5
77	Evaluación económica del empleo de terapias farmacológicas para la cesación en el hábito tabáquico. Gaceta Sanitaria, 2003, 17, 393-403.	1.5	6
78	Information disclosure and smoking risk perceptions: Potential short-term impact on Spanish students of the new European Union directive on tobacco products. European Journal of Public Health, 2002, 12, 295-301.	0.3	15
79	Economic Evaluation of Vaccination Programmes. Pharmacoeconomics, 2002, 20, 1-7.	3.3	77
80	The social cost of illegal drug consumption in Spain. Addiction, 2002, 97, 1145-1153.	3.3	27
81	Smoking Risks in Spain: Part I—Perception of Risks to the Smoker. Journal of Risk and Uncertainty, 2000, 21, 161-186.	1.5	48
82	Smoking Risks in Spain: Part II—Determinants of Smoking Behavior. Journal of Risk and Uncertainty, 2000, 21, 213-234.	1.5	23
83	Smoking Risks in Spain: Part III—Perceptions of Environmental Tobacco Smoke Externalities. Journal of Risk and Uncertainty, 2000, 21, 187-212.	1.5	24
84	Economic evaluation of a mammography-based breast cancer screening programme in Spain. European Journal of Public Health, 1997, 7, 68-76.	0.3	17
85	Cost Effectiveness of Hepatitis A Virus Immunisation in Spain. Pharmacoeconomics, 1997, 12, 361-373.	3.3	25
86	Economic Evaluation Techniques in Healthcare. Pharmacoeconomics, 1997, 12, 501-505.	3.3	0
87	Hospital care for persons with AIDS in the European Union. Health Policy, 1997, 41, 157-176.	3.0	13
88	Vaccination against hepatitis B virus in Spain: a cost-effectiveness analysis. Vaccine, 1997, 15, 1652-1660.	3.8	21
89	Cost-Effectiveness Analysis of Hepatitis B Vaccination Strategies in Catalonia, Spain. Pharmacoeconomics, 1995, 7, 428-443.	3.3	14
90	Economic Analysis of Health Technologies and Programmes. Pharmacoeconomics, 1995, 8, 245-252.	3.3	67

#	ARTICLE	IF	CITATIONS
91	REFLECTIONS AND PERSPECTIVES ON BIOSIMILARS IN BRAZIL. International Journal of Pharmacy and Pharmaceutical Sciences, 0, , 26-31.	0.3	0
92	BIOSIMILAR MEDICINE PRICE ANALYSIS IN BRAZIL: THE ANTIRHEUMATIC CASE. Asian Journal of Pharmaceutical and Clinical Research, 0, , 170-173.	0.3	1